Catalyst
Slingshot members are tracking this event:
Aurinia Announces Preliminary Topline Data From its Open Label Aurion Study in Lupus Nephritis
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| AUPH | Community voting in process | |||||
Additional Information
100% of Patients receiving multi-target therapy with voclosporin achieved at least a 25% reduction of proteinuria at 8 weeks with a mean decrease of 72%
Slingshot Insights Explained
Catalyst Date
Occurred on:
Feb 08, 2016
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Aurion, Active Lupus Nephritis, Egfr, Proteinuria, Biomarkers, Renal Function
